Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Director | January 31, 2022 | January 31, 2022 |
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | July 06, 2026 | July 08, 2026 |
| Forte Biosciences, Inc.TOCA · Entity 9529 | Director | October 04, 2019 | October 05, 2019 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 19, 2025 | May 19, 2025 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date January 31, 2022 · Filed January 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.19 · Expires 2032-01-30 | Direct | 85,000 |
Reported balance
After 2022-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 85,000 · Balance 85,000 F1: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company.
Enliven Therapeutics, Inc.
Report date July 06, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,884 |
Ending reported balance
After 2026-07-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-06 · Sale · Disposed 4,111 · Balance 47,773 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F2: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-07-06 · Sale · Disposed 5,889 · Balance 41,884 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F3: This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
F2: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 7,500 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Nurix Therapeutics, Inc.
Report date May 19, 2025 · Filed May 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2035-05-18 | Direct | 25,000 |
Reported balance
After 2025-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-19 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 40,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Loxo Oncology, Inc.
Report date February 15, 2019 · Filed February 15, 2019
Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-15 · Disposition to issuer · Disposed 27,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-15 · Disposition to issuer · Disposed 49,687 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.91 · Expires 2025-07-27 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-15 · Disposition to issuer · Disposed 4,716 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-15 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.58 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-15 · Disposition to issuer · Disposed 11,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $180.98 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-15 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 8, 2026 21:15 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,889 | $50.84 | $299,421.49 |
DisclosureSEC source: 0001536368-26-000007 · form4-07082026_090742.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,884 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F3 · price: This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 21:15 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,111 | $49.98 | $205,481.76 |
DisclosureSEC source: 0001536368-26-000007 · form4-07082026_090742.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,773 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F2 · price: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 354 | $35.82 | $12,679.82 |
DisclosureSEC source: 0001536368-26-000004 · form4-06092026_080612.xml · nonDerivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,884 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F5 · price: This transaction was executed in multiple trades at prices ranging from $35.7595 to $35.9456. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,867 | $35.36 | $66,012.08 |
DisclosureSEC source: 0001536368-26-000004 · form4-06092026_080612.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,238 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F4 · price: This transaction was executed in multiple trades at prices ranging from $34.759 to $35.7574. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 7,779 | $34.28 | $266,659.45 |
DisclosureSEC source: 0001536368-26-000004 · form4-06092026_080612.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,105 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F2 · price: This transaction was executed in multiple trades at prices ranging from $33.7383 to $34.7358. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: The number of shares held reflects the transfer of 31,172 shares of Common Stock from Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE to the Reporting Person . Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:01 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 17,126 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001536368-26-000003 · form4-02182026_010205.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,126 Underlying: Common Stock · 17,126 shares Expires 2036-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:48 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001536368-26-000002 · form4-01062026_090157.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 15,958 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001536368-25-000007 · form4-12192025_101209.xml · derivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,741 Underlying: Common Stock · 15,958 shares Expires 2030-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 22:58 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 15,958 | $1.12 | $17,872.96 |
DisclosureSEC source: 0001536368-25-000007 · form4-12192025_101209.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 22:35 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001536368-25-000006 · form4-12092025_101258.xml · derivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 10,000 shares Expires 2034-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 22:35 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 10,000 | $7.90 | $79,000.00 |
DisclosureSEC source: 0001536368-25-000006 · form4-12092025_101258.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 22:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 5,534 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001536368-25-000004 · form4-12052025_101227.xml · derivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,534 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 22:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 5,534 | $3.75 | $20,752.50 |
DisclosureSEC source: 0001536368-25-000004 · form4-12052025_101227.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2025 Filed May 19, 2025 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001549595-25-000082 · wk-form4_1747690408.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001415889-25-006616 · form4-03042025_100357.xml · derivative · entry 4 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 27,666 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001415889-25-006616 · form4-03042025_100357.xml · derivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,534 Underlying: Common Stock · 27,666 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 20,500 | $6.33 | $129,765.00 |
DisclosureSEC source: 0001415889-25-006616 · form4-03042025_100357.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:27 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 27,666 | $3.75 | $103,747.50 |
DisclosureSEC source: 0001415889-25-006616 · form4-03042025_100357.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 15,368 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003523 · form4-02102025_100237.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,368 Underlying: Common Stock · 15,368 shares Expires 2035-02-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:46 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001415889-25-000792 · form4-01062025_090135.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 20:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GiftCommon Stock | 54,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000100 · wk-form4_1721333153.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:25 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016913 · form4-06142024_080645.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:48 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001415889-24-015475 · form4-06042024_100642.xml · derivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,200 Underlying: Common Stock · 20,500 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:48 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 20,500 | $3.75 | $76,875.00 |
DisclosureSEC source: 0001415889-24-015475 · form4-06042024_100642.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2024 Filed May 20, 2024 23:26 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $16.19 | $0.00 |
DisclosureSEC source: 0001549595-24-000068 · wk-form4_1716247551.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-19 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 20, 2025, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:39 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 37,882 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0001415889-24-010678 · form4-04112024_120413.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,882 Underlying: Common Stock · 37,882 shares Expires 2034-04-08 F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:56 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 20,500 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001209191-23-037396 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| May 04, 2023 Filed May 4, 2023 23:56 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-23-027507 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 18, 2022 00:23 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 53,700 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001209191-22-038201 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,700 Underlying: Common Stock · 53,700 shares Expires 2032-06-16 F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022. Read SEC document |
| May 05, 2022 Filed May 6, 2022 21:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-22-027662 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-04 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| January 31, 2022 Filed Jan 31, 2022 22:33 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 85,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-22-005689 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common stock · 85,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:48 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 16,625 | $0.00 Strike: $19.03 | $0.00 |
DisclosureSEC source: 0001209191-21-041745 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,625 Underlying: Common Stock · 16,625 shares Expires 2031-06-15 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 16, 2022 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| May 06, 2021 Filed May 24, 2021 23:49 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $27.38 | $0.00 |
DisclosureSEC source: 0001209191-21-035538 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-05-05 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:30 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 33,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-21-006097 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 28, 2022), subject to the director's continued service with the Company. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 21:09 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 28,515 | $0.00 Strike: $35.92 | $0.00 |
DisclosureSEC source: 0001209191-20-035596 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,515 Underlying: Common Stock · 28,515 shares Expires 2030-06-08 F1 · derivative.exercise_date: 1/36 of the shares subject to the option shall vest on each monthly anniversary of the date of grant. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:10 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 180,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-20-016247 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common stock · 180,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (March 2, 2021), subject to the director's continued service with the Company. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:31 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052619 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:24 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001209191-19-033658 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 8,750 | $235.00 Strike: $180.98 | $2,056,250.00 |
DisclosureSEC source: 0001567619-19-004572 · doc1.xml · derivative · entry 6 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2028-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 11,000 | $235.00 Strike: $78.58 | $2,585,000.00 |
DisclosureSEC source: 0001567619-19-004572 · doc1.xml · derivative · entry 5 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2027-06-21 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 3,095 | $235.00 Strike: $24.18 | $727,325.00 |
DisclosureSEC source: 0001567619-19-004572 · doc1.xml · derivative · entry 4 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,095 shares Expires 2026-06-09 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,716 | $235.00 Strike: $20.91 | $1,108,260.00 |
DisclosureSEC source: 0001567619-19-004572 · doc1.xml · derivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,716 shares Expires 2025-07-27 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 49,687 | $235.00 Strike: $3.65 | $11,676,445.00 |
DisclosureSEC source: 0001567619-19-004572 · doc1.xml · derivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,687 shares Expires 2024-06-18 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 14:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 27,344 | $235.00 Strike: $3.65 | $6,425,840.00 |
DisclosureSEC source: 0001567619-19-004572 · doc1.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,344 shares Expires 2024-06-18 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:38 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 14,800 | $1.05 | $15,581.44 |
DisclosureSEC source: 0001209191-19-005351 · doc4.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,200 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations. F2 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.095, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4. F3 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 21, 2019 Filed Jan 23, 2019 21:48 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 180,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-19-004985 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-01-20 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest in twelve equal monthly installments beginning on February 21, 2019 until the award becomes fully vested on January 21, 2020, subject to the director's continued service with the Company. Read SEC document |
| January 11, 2019 Filed Feb 26, 2019 21:49 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $9.27 | $0.00 |
DisclosureSEC source: 0001209191-19-013586 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Acting-Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-01-10 F1 · derivative.exercise_date: The stock option vests in full on May 26, 2019. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:05 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-003657 · doc1.xml · derivative · entry 4 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,344 Underlying: Common Stock · 5,000 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The stock option is fully vested and is immediately exercisable. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:05 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $171.90 | $85,948.00 |
DisclosureSEC source: 0001567619-18-003657 · doc1.xml · nonDerivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.38 to $172.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:05 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 4,500 | $170.20 | $765,881.10 |
DisclosureSEC source: 0001567619-18-003657 · doc1.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.00 to $170.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.